United Kingdom Genetic Testing Market Outlook to 2021
Description-
Summary
GlobalDatas
new report, "United Kingdom Genetic
Testing
Market Outlook to 2021", provides key market data on the United
Kingdom Genetic Testing market. The report provides value, in
millions of US dollars within market segments - Acquired Gene or
Chromosome Alterations, Inborn Gene or Chromosome Alterations and
Other Genetic Tests.
The
report also provides company shares and distribution shares data for
the market category, and global corporate-level profiles of the key
market participants. Based on the availability of data for the
particular category and country, information related to pipeline
products, news and deals is available in the report.
Extensive
interviews are conducted with industry experts to validate the market
size, company share and distribution share data and analysis.
Scope
-
Genetic Testing market includes Acquired Gene or Chromosome
Alterations, Inborn Gene or Chromosome Alterations and Other Genetic
Tests.
-
Annualized market revenues (USD million) data for each of the market
categories. Data is provided from 2007 to 2014 and forecast to 2021.
-
2014 company shares and distribution shares data for Genetic Testing
market.
-
Global corporate-level profiles of key companies operating within the
United Kingdom Genetic Testing market.
-
Key players covered include F. Hoffmann-La Roche Ltd., Siemens
Healthcare, Danaher Corporation, Abbott Laboratories, Hologic, Inc.,
Cepheid, Bio-Rad Laboratories, Inc., Qiagen N.V., Transgenomic, Inc.
and PerkinElmer, Inc.
Reasons
to buy
-
Develop business strategies by identifying the key market segments
poised for strong growth in the future.
-
Develop market-entry and market expansion strategies.
-
Design competition strategies by identifying who-stands-where in the
market.
-
Develop investment strategies by identifying the key market segments
expected to register strong growth in the near future.
-
What are the key distribution channels and whats the most preferred
mode of product distribution - Identify, understand and capitalize.
Table
of Contents
6
Financial Deals Landscape 22
6.1
Asset Transactions 22
6.1.1
Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property
from Isis Innovation for USD14.5 Million 22
6.2
Partnerships 24
6.2.1
Cytox Enters into Joint Development Partnership with Affymetrix 24
6.2.2
Atlas Genetics Enters into Agreement with Pharma Company 25
6.2.3
KromaTiD Enters into Distribution Agreement with Tebu-bio 26
6.2.4
Affymetrix Enters into Licensing Agreement with Peptide Groove 27
6.3
Venture Financing 28
6.3.1
Abingdon Health Raises USD3.4 Million in Venture Financing 28
7
Appendix 30
7.1
Research Methodology 31
7.1.1
Coverage 31
7.1.2
Secondary Research 31
7.1.3
Primary Research 31
7.1.4
Company Share Analysis 32
7.1.5
Distribution Share Analysis 32
7.2
GlobalData Consulting 32
7.3
Contact Us 32
7.4
Disclaimer 33
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Website: http://www.researchmoz.us
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Website: http://www.researchmoz.us
Comments
Post a Comment